Analysts have been eager to weigh in on the Healthcare sector with new ratings on Bioxcel Therapeutics (BTAI), Fate Therapeutics (FATE) and Cortexyme (CRTX).
Bioxcel Therapeutics (BTAI)
In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Bioxcel Therapeutics, with a price target of $185.00. The company’s shares closed last Tuesday at $51.37.
According to TipRanks.com, Selvaraju is a top 25 analyst with an average return of 39.4% and a 76.0% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Protalix Biotherapeutics, NeuroBo Pharmaceuticals, and Inovio Pharmaceuticals.
Bioxcel Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $112.25.
See today’s analyst top recommended stocks >>
Fate Therapeutics (FATE)
In a report released today, Robert Burns from H.C. Wainwright initiated coverage with a Hold rating on Fate Therapeutics and a price target of $108.00. The company’s shares closed last Tuesday at $89.31.
According to TipRanks.com, Burns is a 5-star analyst with an average return of 46.5% and a 70.2% success rate. Burns covers the Healthcare sector, focusing on stocks such as Forma Therapeutics Holdings, Black Diamond Therapeutics, and Turning Point Therapeutics.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Fate Therapeutics with a $95.85 average price target, a -0.9% downside from current levels. In a report issued on January 25, BMO Capital also maintained a Hold rating on the stock with a $88.00 price target.
Cortexyme (CRTX)
In a report released today, Andrew Fein from H.C. Wainwright reiterated a Buy rating on Cortexyme, with a price target of $76.00. The company’s shares closed last Tuesday at $37.36.
According to TipRanks.com, Fein is a 5-star analyst with an average return of 22.2% and a 59.6% success rate. Fein covers the Healthcare sector, focusing on stocks such as DBV Technologies SA – American, Deciphera Pharmaceuticals, and Global Blood Therapeutics.
Cortexyme has an analyst consensus of Moderate Buy, with a price target consensus of $96.00, a 201.8% upside from current levels. In a report released today, Canaccord Genuity also maintained a Buy rating on the stock with a $75.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
